Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com
Novel, Noninvasive Skin Cancer Detection Method Shows Promise

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Michael Kolodziej on How Technology Will Improve Patient Access to Clinical Trials
October 9th 2017

Dr Michael Kolodziej on How Technology Will Improve Patient Access to Clinical Trials

Technological advances will lead to improvements in clinical trials and greater participation in trials by patients, explained Michael Kolodziej, MD, national medical director of managed care strategy at Flatiron Health.
Podcast: This Week in Managed Care - Finding a New HHS Secretary, and Other Health News
October 7th 2017

Podcast: This Week in Managed Care - Finding a New HHS Secretary, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
October 6th 2017

CDC Calls Attention to Connections Between Obesity and Cancer

Mary Caffrey
The US Preventive Services Task Force already has recommendations for screening and intervention for obesity, but they often are not followed.
This Week in Managed Care: October 6, 2017
October 6th 2017

This Week in Managed Care: October 6, 2017

This week, the top managed care stories included speculation regarding who would replace Tom Price, MD, as HHS secretary; a report on breast cancer mortality trends and racial disparities from 1989 to 2015; and the FDA announced new strategies to improve patient access to less expensive drugs.
Site Logo
October 6th 2017

European Study Questions Survival, QOL Benefit of Marketed Cancer Drugs

Surabhi Dangi-Garimella, PhD
A new study in the journal BMJ concludes that most oncology drugs approved by the European Medicines Agency between 2009 and 2013 failed to display a benefit on survival or quality of life, even at 3.3 years following market entry.
Tesh Khullar: Community Oncologists Have to Be Business Experts to Stay Alive
October 6th 2017

Tesh Khullar: Community Oncologists Have to Be Business Experts to Stay Alive

As the health system evolves it will become increasingly important that practices understand business, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
Site Logo
October 5th 2017

Timing, Sequence Critical for Efficacy of Combination Immunotherapy Treatment

Surabhi Dangi-Garimella, PhD
A research study conducted in a mouse mammary cancer model has found that optimal timing, based on sequencing of immunotherapy agents, is important for treatment efficacy.
Site Logo
October 5th 2017

Survey Quantifies Precision Medicine Awareness Among Health System Leaders

Surabhi Dangi-Garimella, PhD
A new survey conducted by The Health Management Academy has identified a rapid investment by leading healthcare systems in precision medicine programs, with significant expectations of the impact of real-world outcomes on physician decision making.
Site Logo
October 4th 2017

Fas Biomarker Predicts Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma

AJMC Staff
Aaron Lyss on Challenges When Transitioning to Value-Based Payments
October 4th 2017

Aaron Lyss on Challenges When Transitioning to Value-Based Payments

There are 2 categories of challenges facing oncology practices as they transition to value-based payment models, said Aaron Lyss, director of value-based care for Tennessee Oncology.
Site Logo
October 4th 2017

Drop in Breast Cancer Death Rate Saved More Than 322,000 Lives From 1989 to 2015

Laura Joszt, MA
While death rates from breast cancer declined 39% from 1989 to 2015, there are clear racial differences with black women having higher breast cancer death rates than white women, according to a new report from the American Cancer Society.
Site Logo
October 3rd 2017

ASCO, Friends of Cancer Research Call for More Inclusive Cancer Clinical Trials

Christina Mattina
Clinical trials researching cancer therapies should be more inclusive of a broader range of patients, according to the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research.
Site Logo
October 2nd 2017

Updates to Treatment Options During Breast Cancer Awareness Month

Surabhi Dangi-Garimella, PhD
October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.
Dan Todd Highlights Policy Changes Community Oncologists Should Look Out For
October 2nd 2017

Dan Todd Highlights Policy Changes Community Oncologists Should Look Out For

Drug pricing is one area where there may be potential future policy changes that impact community oncologists, said Dan Todd, JD, principal at Todd Strategy.
Site Logo
October 1st 2017

Study Finds Outreach Interventions Effective for CRC Screenings

Alison Rodriguez
Outreach interventions, including mail outreach invitations, may be effective in increasing the proportion of completed colorectal cancer screening, according to research.
Podcast: This Week in Managed Care - Latest ACA Repeal Fails, and Other Health News
September 30th 2017

Podcast: This Week in Managed Care - Latest ACA Repeal Fails, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Site Logo
September 29th 2017

5 Takeaways for Payers and Providers From the NCCN Meeting on Quality Metrics

Surabhi Dangi-Garimella, PhD
Key lessons learnt at the National Comprehensive Cancer Network's policy meeting: Redefining Quality Measurement in Oncology.
Site Logo
September 29th 2017

Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned

Surabhi Dangi-Garimella, PhD
Ensuring access to appropriate data and then using the information to improve healthcare outcomes remains an ongoing challenge-this was the conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology.
This Week in Managed Care: September 29, 2017
September 29th 2017

This Week in Managed Care: September 29, 2017

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.
Site Logo
September 29th 2017

Report Finds Hospitals Costlier for Cancer Care Than Community Practices

Christina Mattina
Not only do patients with cancer incur higher costs when treated in the hospital outpatient setting compared with community oncology practices, they also have higher rates of emergency department visits, according to a recent study.
Site Logo
September 28th 2017

Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types

Christina Mattina
After examining over 1000 cases of high-grade gliomas in children and young adults, researchers have split these rare brain tumors into at least 10 different subtypes, which could help clinicians choose and deliver more effective treatments.
Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation
September 28th 2017

Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation

As clinical trials get more complex and fewer patients are available to participate in any particular trial, technology is going to be critical for improving patient access to trials and making the whole process of being on a trial easier for patients and physicians, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Site Logo
September 28th 2017

Early Imaging Can Identify Positive Immunotherapy Responders in Advanced Melanoma

Surabhi Dangi-Garimella, PhD
Combining positron emission tomography and computed tomography early in the treatment plan for patients diagnosed with advanced melanoma can help identify the potential benefit of a specific immunotherapy and avoid the risk of non-beneficial intervention.
Site Logo
September 27th 2017

Research Finds Cancer Survivorship Care Lacking in Advanced Primary Care Practices

Christina Mattina
A new case study of 12 advanced primary care practices found that none provided comprehensive cancer survivorship care, which the authors attributed to insufficient information systems and difficulties identifying survivors.
Site Logo
September 27th 2017

Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development

Alison Rodriguez
Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies-First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” took a look at the pipeline.
Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge
September 26th 2017

Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge

While the healthcare industry moves more toward value-based payment models, oncology practices are at a disadvantage because few payers truly understand the nuances of cancer care to design good oncology payment models, explained Aaron Lyss, director of value-based care for Tennessee Oncology.
Site Logo
September 26th 2017

Title X Health Centers Reducing Cervical Cancer Screening in Accordance With Guidelines

Christina Mattina
Among women treated at health centers receiving federal funding under Title X, the proportion receiving cervical cancer screening tests declined significantly from 2005 to 2015, according to new research.
Site Logo
September 26th 2017

Lending the Patient Voice to Oncology Quality Measurement

Surabhi Dangi-Garimella, PhD
At the National Comprehensive Cancer Network's Oncology Policy Summit, a physician administrator from the MD Anderson Cancer Center discussed weaving the patient focus into outcomes measurements.
Site Logo
September 25th 2017

JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy

Christina Mattina
While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.
Site Logo
September 25th 2017

New Advance Value Framework Offered as a Decision-Support Tool for Reimbursement

Surabhi Dangi-Garimella, PhD
Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.
<1
...
646566676869707172
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo